Name: Stryker Corp. (NYSE:SYK) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Download chart

Stryker Corp., income statement, revenues

US$ in millions

12 months ended:	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
MedSurg and Neurotechnology	9,538)	8,345)	8,475)	—)	—)
Orthopaedics and Spine	7,570)	6,006)	6,409)	—)	—)
Net sales	17,108)	14,351)	14,884)	—)	—)

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Net sales experienced a slight contraction between 2019 and 2020, followed by a substantial increase in 2021. This trajectory indicates a period of short-term volatility followed by a strong recovery and acceleration in revenue generation.

Overall Net Sales Trend: Total net sales declined from 14,884 million USD in 2019 to 14,351 million USD in 2020, representing a decrease of approximately 3.6%. This trend reversed sharply in 2021, with net sales climbing to 17,108 million USD, marking a growth of 19.2% relative to the 2020 fiscal year.
MedSurg and Neurotechnology Segment Analysis: The MedSurg and Neurotechnology segment demonstrated relative resilience. A marginal decrease was observed from 8,475 million USD in 2019 to 8,345 million USD in 2020. Growth resumed in 2021, with revenues reaching 9,538 million USD, an increase of approximately 14.3% from the prior year.
Orthopaedics and Spine Segment Analysis: Greater volatility is evident in the Orthopaedics and Spine segment. Revenue decreased from 6,409 million USD in 2019 to 6,006 million USD in 2020, a decline of approximately 6.3%. This segment exhibited the most significant rebound in 2021, with sales rising to 7,570 million USD, representing a growth rate of roughly 26%.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?